Aspirin and NSAID Use and Ovarian Cancer Prognosis: A Molecular Epidemiological Study
Abstract
This research focuses on identifying modifiable lifestyle factors that could be used to improve the prognosis for ovarian cancer patients. The hypothesis is that ovarian cancer patients who regularly use aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) after their diagnosis may benefit from an improvement in survival. Using data from the Ovarian Cancer Cohort Consortium the study aims to: identify optimal patterns of aspirin/NSAID use (frequency of use and aspirin dose) to maximize the prognostic impact; and define the types of patients who are most likely to have prognostic benefit from aspirin/NSAID use based on their personal (weight) or tumor characteristics (histology or tumor markers). In the time period captured in this technical report (Oct-Dec 2021), progress has been made to prepare the Ovarian Cancer Cohort Consortium dataset by setting up data and material transfer agreements, requesting clinical data on ovarian cancer patients and harmonizing data from the participating cohort studies. The ultimate goal of this study is to advance knowledge about how inflammation promotes the progression of ovarian cancer and to offer new insights into how inflammation can be counteracted through the use of aspirin/NSAIDs after diagnosis to improve the prognosis for ovarian cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1173825
Entities
People
- Melissa Merritt
Organizations
- University of Hawaiʻi System